Why is Haemonetics stock surging today?
Haemonetics (HAE) shares rose about 6.6% in pre-open after the company filed an 8-K for a non-exclusive supply agreement with CSL Plasma. The deal lets CSL deploy Haemonetics NexSys PCS devices with Persona PLUS and buy related disposables at U.S. centers. Investors also cited Haemonetics’ Aug. 6 Q1 FY2027 results: $339.4M revenue, $1.14 adjusted EPS, and raised FY2027 growth guidance to 5%–8%, plus analyst target increases.
How this was made
The 30-second read
Why it matters
The combination of a newly filed 8-K supply agreement, an earnings-driven FY2027 guidance increase, and analyst target hikes provides a coherent catalyst stack for a re-rating.
Market read
This is a same-day, company-specific catalyst tied to a formal supply agreement and guidance upgrade, explaining the pre-market surge.
What to watch
The article does not provide pricing, device deployment timelines, or expected disposable volumes, which are key to validating the plasma growth catalyst.
Background
Haemonetics previously lost CSL as a customer, and the new agreement formalizes a non-exclusive supply relationship for NexSys PCS devices and Persona PLUS technology.
Ticker impact
Haemonetics shares surged after filing an 8-K for a non-exclusive CSL Plasma supply deal using NexSys PCS devices and Persona PLUS tech.
Likely supports continued upside bias in the near term, with follow-through dependent on any incremental commentary on expected volumes.
The article cites a same-day 8-K supply agreement and links it to a guidance upgrade and analyst target increases, all of which can drive immediate repricing.
Market effects
Strengthens the read-through for plasma collection equipment and disposables demand, potentially improving sentiment toward adjacent medtech/plasma supply chains.
Primarily US-listed single-name repricing; broader index weakness limits spillover.
CSL Plasma is global-scale, so successful device deployment could matter for international plasma operations, though the article is US-focused.
Counterpoint
No minimum purchase commitments mean the deal may not translate into near-term volume, so the move could partially fade if investors demand quantified ramp.
Key entities
- companyHaemonetics
Subject of the article; filed an 8-K for a CSL Plasma supply agreement and recently reported Q1 FY2027 results with guidance raised.
- customer/partnerCSL Plasma
Plasma collection operator that will deploy Haemonetics NexSys PCS devices with Persona PLUS technology and buy related disposables.
- market researchBofA survey
Cited as showing investors are extremely bullish, supporting the sentiment backdrop for the move.
